Beijing Tong Ren Tang Chinese Medicine Past Earnings Performance
Past criteria checks 1/6
Beijing Tong Ren Tang Chinese Medicine has been growing earnings at an average annual rate of 1.6%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 3.8% per year. Beijing Tong Ren Tang Chinese Medicine's return on equity is 13.4%, and it has net margins of 35.9%.
Key information
1.6%
Earnings growth rate
1.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 3.8% |
| Return on equity | 13.4% |
| Net Margin | 35.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up
Oct 04
Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders
Sep 06Is There An Opportunity With Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 31% Undervaluation?
Sep 02Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk
Feb 05Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Jan 03A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Sep 28Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today
Jul 12Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?
Mar 29Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28
Apr 28Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28
Mar 25Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?
Oct 27Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 28Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Mar 11What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Feb 04Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?
Jan 18
Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?
Dec 29Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Dec 11Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Nov 23Revenue & Expenses Breakdown
How Beijing Tong Ren Tang Chinese Medicine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,377 | 494 | 448 | 0 |
| 31 Mar 24 | 1,451 | 517 | 440 | 0 |
| 31 Dec 23 | 1,525 | 540 | 431 | 0 |
| 30 Sep 23 | 1,721 | 619 | 408 | 0 |
| 30 Jun 23 | 1,918 | 697 | 384 | 0 |
| 31 Mar 23 | 1,824 | 672 | 366 | 0 |
| 31 Dec 22 | 1,731 | 646 | 348 | 0 |
| 30 Sep 22 | 1,605 | 601 | 343 | 0 |
| 30 Jun 22 | 1,478 | 555 | 337 | 0 |
| 31 Mar 22 | 1,517 | 582 | 343 | 0 |
| 31 Dec 21 | 1,556 | 608 | 349 | 0 |
| 30 Sep 21 | 1,504 | 595 | 343 | 0 |
| 30 Jun 21 | 1,452 | 583 | 337 | 0 |
| 31 Mar 21 | 1,384 | 563 | 324 | 0 |
| 31 Dec 20 | 1,315 | 542 | 311 | 0 |
| 30 Sep 20 | 1,246 | 483 | 314 | 0 |
| 30 Jun 20 | 1,178 | 424 | 317 | 0 |
| 31 Mar 20 | 1,305 | 490 | 340 | 0 |
| 31 Dec 19 | 1,433 | 556 | 364 | 0 |
| 30 Sep 19 | 1,505 | 594 | 376 | 0 |
| 30 Jun 19 | 1,577 | 632 | 387 | 0 |
| 31 Mar 19 | 1,546 | 601 | 378 | 0 |
| 31 Dec 18 | 1,514 | 581 | 381 | 0 |
| 30 Sep 18 | 1,466 | 552 | 373 | 0 |
| 30 Jun 18 | 1,402 | 540 | 340 | 0 |
| 31 Mar 18 | 1,330 | 516 | 335 | 0 |
| 31 Dec 17 | 1,266 | 490 | 314 | 0 |
| 30 Sep 17 | 1,212 | 469 | 309 | 0 |
| 30 Jun 17 | 1,166 | 449 | 301 | 0 |
| 31 Mar 17 | 1,134 | 444 | 284 | 0 |
| 31 Dec 16 | 1,084 | 420 | 272 | 0 |
| 30 Sep 16 | 1,063 | 431 | 247 | 0 |
| 30 Jun 16 | 1,028 | 410 | 237 | 0 |
| 31 Mar 16 | 1,002 | 380 | 239 | 0 |
| 31 Dec 15 | 970 | 354 | 232 | 0 |
| 30 Sep 15 | 939 | 337 | 236 | 0 |
| 30 Jun 15 | 881 | 320 | 226 | 0 |
| 31 Mar 15 | 834 | 304 | 216 | 0 |
| 31 Dec 14 | 761 | 287 | 201 | 0 |
| 30 Sep 14 | 733 | 286 | 173 | 0 |
| 30 Jun 14 | 699 | 267 | 167 | 0 |
| 31 Mar 14 | 652 | 249 | 156 | 0 |
| 31 Dec 13 | 614 | 220 | 157 | 0 |
Quality Earnings: 3613 has a high level of non-cash earnings.
Growing Profit Margin: 3613's current net profit margins (35.9%) are lower than last year (36.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3613's earnings have grown by 1.6% per year over the past 5 years.
Accelerating Growth: 3613's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 3613 had negative earnings growth (-29.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6.4%).
Return on Equity
High ROE: 3613's Return on Equity (13.4%) is considered low.